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Abstract
We report the crystal structures at 2.05 and 2.45 A˚ resolution of two antibodies, 13G10 and 14H7, directed against an
iron(III)-aaab-carboxyphenylporphyrin, which display some peroxidase activity. Although these two antibodies differ by
only one amino acid in their variable l-light chain and display 86% sequence identity in their variable heavy chain, their
complementary determining regions (CDR) CDRH1 and CDRH3 adopt very different conformations. The presence of Met or
Leu residues at positions preceding residue H101 in CDRH3 in 13G10 and 14H7, respectively, yields to shallow combining
sites pockets with different shapes that are mainly hydrophobic. The hapten and other carboxyphenyl-derivatized iron(III)-
porphyrins have been modeled in the active sites of both antibodies using protein ligand docking with the program GOLD.
The hapten is maintained in the antibody pockets of 13G10 and 14H7 by a strong network of hydrogen bonds with two or
three carboxylates of the carboxyphenyl substituents of the porphyrin, respectively, as well as numerous stacking and van
der Waals interactions with the very hydrophobic CDRH3. However, no amino acid residue was found to chelate the iron.
Modeling also allows us to rationalize the recognition of alternative porphyrinic cofactors by the 13G10 and 14H7
antibodies and the effect of imidazole binding on the peroxidase activity of the 13G10/porphyrin complexes.
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Introduction
Hemoproteins contain iron-protoporphyrin IX or heme as the
prosthetic group, whose divalent iron atom can reversibly bind
molecules such as molecular oxygen, leading to a wide range of
biological functions [1]. Chemical or biotechnological models of
hemoproteins have thus long been developed in order to create
selective catalysts for industrial and fine chemistry and to predict
the oxidative metabolism of new drugs [2,3,4,5]. Examples include
the de novo design of heme proteins, including that of membrane-
soluble proteins [6,7]. Peroxidases appear to be the easiest
hemoproteins to be mimicked. Indeed, their active site consists
of the iron(III)-porphyrin moiety encapsulated in the apoprotein.
On one side, the heme iron is bound to an axial histidine residue
(proximal ligand) and on the other side to the peroxide substrate to
lead to an iron-oxo complex. The radical cation on the iron (IV)-
oxo porphyrin ring can be delocalized onto proximal protein side
chains [8]. The reducing cosubstrate does not bind to a well-
defined site on the inside of the protein, as peroxidases restrict
access of substrates to the heme-oxo complex, so that the electron
transfer occurs to the meso edge of the heme [9]. Heterolytic
cleavage of the O-O bond is assisted by general acid base catalysis
through the concerted action of the distal histidine and arginine
residues [10]. A major problem in homogeneous metalloporphyrin
systems mimicking hemoproteins is that the catalyst is often
destroyed by oxidation during the course of the reaction and it is
difficult to combine reactivity and selectivity in these models. The
use of a protein such as xylanase A [11] or an antibody mimicking
the protein matrix of heme enzymes not only prevents aggregation
and intermolecular self-oxidation of the catalyst, but can also
influence the selectivity of the reaction [12]. As the antibody has
the role of a host molecule that enhances the function of
porphyrin, the porphyrin itself can be used as the hapten to
induce the antibodies.
In order to generate antibodies with peroxidase activity, mice
have been immunized against iron(III)-a,a,a,b-meso-tetrakis-ortho-
carboxyphenyl-porphyrin (Fe(ToCPP)) (Figure 1) [13,14]. Two
antibodies, 13G10 and 14H7, were found to bind the porphyrin
hapten with nanomolar affinities and enhance its peroxidase
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activity. The 13G10-Fe(ToCPP) and 14H7-Fe(ToCPP) complexes
catalyzed the oxidation of 2,29-azinobis (3-ethylbenzothiazoline-6-
sulfonic acid) (ABTS) 5 to 8 fold more effectively than the cofactor
alone, with kcat reaching 540 min
21 and kcat/Km
(ABTS) 6.2
104 M21 min21 at pH 4.6 for the 13G10 complex [15]. The
antibodies protected the cofactor from oxidative degradation,
allowing more than one thousand turnovers before destruction. In
addition, it was shown that the 13G10-Fe(ToCPP) complex
possessed a remarkably thermostable peroxidase activity and that
it was able to use not only H2O2 as the oxidant but also a wide
range of hydroperoxides [15,16]. Compared with the peroxidase
enzymes, the two antibodies possess a low affinity toward H2O2
(Km = 9–16 mM) but a higher affinity than the cofactor alone
(Km = 42 mM) [13]. Because no amino acid was found to
coordinate the iron atom in the 13G10 and 14H7/Fe(ToCPP)
complexes [14], it was thought that an imidazole ligand could
mimic the proximal histidine of peroxidases and enhance the
catalytic activity. Fe(ToCPP) and less hindered iron(III)-tetraar-
ylporphyrins, bearing only one or two carboxyphenyl substituents,
were found to bind only one imidazole ligand when complexed to
antibody 13G10, suggesting that the complexes are good mimics
for peroxidases [16]. Whereas 50 mM imidazole inhibited the
peroxidase activity of the 13G10-Fe(ToCPP) complex, it increased
that of 13G10 in complex with porphyrins bearing two meso-
[ortho-carboxyphenyl] substituents by a factor 15.
To get insight into the structural basis for the different binding/
activities of the variously substituted porphyrins, we have
determined the crystal structure of the fragment antigen binding
(Fab) of antibodies 13G10 and 14H7 and modeled their
interaction with the different iron-porphyrins using molecular
docking.
Materials and Methods
Purification and Characterization of Fabs 13G10 and
14H7
The antibodies were produced in ascitic fluid as described [13].
After ammonium sulfate precipitation, the IgGs (IgG1, l) were
loaded on a protein A column in 3 M NaCl, 1.5 M glycine pH 8.9
and eluted by 0.1 M citrate pH 5. The Fab 13G10 (resp. 14H7)
was generated by papain digestion of the antibody at 37uC under
standard conditions (30 mM Tris pH 7.4, 138 mM NaCl,
1.25 mM EDTA, 1.5 mM 2-mercaptoethanol) using a 3% papain
to antibody ratio (w/w) and a 10 h (resp. 8 h) digestion time.
Undigested IgG and Fc fragment were removed by DEAE anion
exchange chromatography followed by gel filtration on a
Sephacryl S100 HR column. The Fabs were further purified by
ion exchange chromatography on a mono Q FPLC column by a
NaCl gradient in 20 mM bistrispropane buffer at pH 7.2 for Fab
14H7 or in 20 mM diethanolamine buffer at pH 8.8 for Fab
13G10.
Sequence Determination
N-terminal sequencing of the H chain of 13G10 showed that the
first three amino acid residues of the Fab were missing. mRNA
from 13G10 hybridoma cells (4 106 cells) were isolated using a
mRNA purification kit from Dynal. cDNAs were prepared in 50ml
using the Omniscript Reverse Transcriptase kit from Qiagen and
stored at 220uC until use. The heavy chain variable region
fragment (about 420 bp) of each cDNA was amplified using a set
of 12 forward primers MHV1 to MHV12 previously described
[17] and reverse primer IgG1: 59GGATCCCGGGCCAGTG-
GATAGACAGATG complementary to the beginning of the
constant region. The l-light chain fragment (about 690 bp) of
each cDNA was amplified using a mixture of 2 forward primers,
NL1: 59ATGGCCTGGATTTCACTTATAC and NL2:
59ATGGCCTGGACTCCTCTCTTC, corresponding to mouse
l-light chain leader sequence, and a mixture of 4 reverse primers,
CL1 59GCAGGAGACAGACTCTTCTCCAC, CL2 59GCAC-
GAGACAGACTCTTCTCCAC, CL3 59GCAGGGGA-
CAAACTCTTCTCCAC, and CL4 59GCACGGGA-
CAAACTCTTCTCCAC, complementary to mouse CLterminal
sequence.
Each cDNA mixture (3 ml) was amplified with the Polymerase
Chain Reaction [18] using TFL polymerase (Promega) on a MJ
Research mini cycler with the following programm. A 10 min
denaturation step at 94uC was followed by 30 cycles of 30 sec
denaturation at 94uC, 45 sec hybridization at 59uC and 1 min
30 sec elongation at 72uC, a final step of 10 min at 72uC was
performed to ensure completion of the amplification. Amplified
products were purified on 0.8% low melting agarose (Sigma) and
ligated into pGEMHTeasy vector (Promega). Electrocompetent E.
coli TG1 cells {D(lac pro) supE thi hsdD5 F’ traD35 proAB LacIq
LacZDM15} were transformed with the ligation mixture by
electroporation using a Cell porator electroporation system
equipped with a Voltage Booster (Life technologies) according to
manufacturer’s recommendations. Plasmid DNAs were extracted
from transformed cells and submitted to dideoxy sequencing [19].
For each antibody, clones were originated from at least two
independant Polymerase Chain Reactions.
Crystallization
Crystals of 13G10 were grown in 26.5% PEG 2000, 0.2 M
MgCl2, 0.1 M Tris pH 8.5, 10% glycerol. Crystals were flash
cooled in a nitrogen stream at 100 K in the same solution
containing 10% glycerol. Crystals of 14H7 were grown in 25%
PEG 4000, 0.1 M ammonium acetate, 0.1 M sodium cacodylate
pH 6.5. A single capillary-mounted crystal kept at 4uC was used
for data collection. This explains the low redundancy for the 14H7
data.
X-Ray data collection and structure
determination. Diffraction data for Fab 13G10 and Fab
14H7 were recorded at the ID14-1 station of ESRF and the
Figure 1. General structures of the cofactors used in this work.
R1a = R2a = R3a = R4b = COOH, R2b =H: iron(III)- a,a,a,b-mesotetrakis-
orthocarboxyphenyl-porphyrin Fe(ToCPP) hapten used to induce the
antibodies 13G10 and 14H7; R1a=R2a=COOH, R2b=R3a=R4b=H: aa-
Fe(DoCPP); R1a = R2b = COOH, R2a = R3a = R4b = H: ab-Fe(DoCPP);
R1a=COOH, R2a=R2b=R3a=R4b=H: Fe(MoCPP).
doi:10.1371/journal.pone.0051128.g001
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LURE DW32 station, respectively. Data were processed with
DENZO and SCALEPACK [20] (Table 1). The structures were
solved by molecular replacement with the program AMoRe [21];
the models used were the Fv domain (PDB code 1mfa) and the
CL-CH1 dimer (PDB code 1mfe) of the murine anticarbohydrate
antibody Se155-4, which belongs to the same IgG1, l class [22].
The atomic model of 13G10 was refined alternating cycles of
model reconstruction with O [23] and refinement with CNS [24],
whereas the atomic model of 14H7 was refined alternating cycles
of model reconstruction with COOT and refinement with PHENIX
[25] using the twin option. The final refinement statistics are given
in Table 1. Several residues at the N-terminus of the heavy chain
and CDRH1 of four heavy chains that were disordered were not
included in the model. Figures were drawn with PYMOL. ThrL51
in CDRL2, which lies in the disallowed region of the Ramachan-
dran plot, belongs to a c turn, as commonly observed in all
antibody structures.
Molecular Modeling
Quantum mechanical calculations were carried out to model
the structures of the tetra-, bi- and mono substituted porphyrins.
These structures were fully optimized with the density functional
B3LYP [26,27], as implemented in Gaussian09 [28]. The double-z
basis set LANL2DZ [29] and its associated pseudo potential were
used for the iron and the split valence 6–31 g** [30,31] for the
other atoms (C, N, H and O). Calculations were carried out for the
high spin ferric species with the iron coordinated by the four
porphyrin nitrogen atoms. The structures of the 13G10 and 14H7
antibodies were processed with the UCSF Chimera package [32]
prior to docking in order to remove the water, ions and glycerol
molecules, calculate the protonation states of the amino acids and
add hydrogen atoms. Protein-ligand dockings were undertaken for
both antibody structures following a recently published protocol
that accounts for the presence of the metal in the ligand [33].
Calculations were carried out using the program GOLD (version
Table 1. Data collection and refinement statistics for Fab 13G10 and 14H7.
Data collection Fab13G10 Fab14H7
Space group C2 P21
Number of molecules in the asymmetric unit 1 8
unit cell a = 55.8 A˚, b = 62.7 A˚, c = 113.5 A˚ a = 56.2 A˚, b = 228.2 A˚, c = 146.6 A˚
a= 90, b=91.7u, c= 90u a= 90, b= 90.1u, c= 90u
resolution 25–2.05 A˚ 20–2.55 A˚
(outer resolution shell) 2.09–2.05 A˚ 2.64–2.55 A˚
unique reflections 23580 111576
completeness* 93.7% (91.4%) 93.7% (87.8%)
mean I/sigma* 23.7 (4.6) 7.4 (2.1)
Rsym* 0.037 (0.19) 0.109 (0.51)
redundancy* 2.5 (2.1) 1.2 (1.2)
Refinement statistics
resolution 20.0–2.05 20.0–2.45
protein residues 425 3356
water molecules 188 359
glycerol molecules 3 –
Mg2+ molecule 1 –
Rcryst 0.224 0.279
Rfree{ 0.275 0.328
Deviations from ideal geometry (rms)
bond length deviation (A˚) 0.008 0.003
bond angle deviation (u) 1.52 0.75
B values
Average B value of protein atoms (A˚2) 49.0 46.5
Average B value of water molecules (A˚2) 51.1 25.5
Average B value of glycerol (A˚2) 76.3 –
B value of Mg2+ (A˚2) 45.0 –
Ramachandran plot
Most favored (%) 86.1 79.6
Additionally allowed (%) 11.4 17.5
Generously allowed (%) 1.1 1.4
Disallowed (%) 1.4 1.5
*Values for highest-resolution shell are given in parentheses.
{4.5% and 4.7% of the data were set aside for the Rfree calculation during the entire refinement.
doi:10.1371/journal.pone.0051128.t001
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5.1) [34] and the Chemscore [35] scoring function. The metal ion
was modeled thanks to an in house parameterization of an
additional atom type in GOLD, which mimics the chelating
capacity of the metal by interacting with amino acids with
potential Lewis basis capacities. For the docking of imidazole, the
parameters of the Chemscore scoring function used for the iron
atom were that of cytochrome P450, as implemented in
GOLD5.0. Because the Mg2+ ion lies at the interface between
the hypervariable loops in the structure of 13G10 and probably
mimics the iron of the porphyrin hapten, the docking calculations
were performed using a 20 A˚ sphere around the Nd atom of the
neighboring residue AsnH33. Based on initial rigid dockings, full
flexibility was allowed for TyrL34 using the Dunbrack rotamer
library [36]. The bonds between the carboxyphenyl groups and
the porphyrin moiety were frozen to maintain the correct a/b
configuration. For each docking, an in house approach, based on a
statistical analysis of a large PDB set of metal-bound proteins, was
used in order to identify those residues that could directly bind to
the metal. Based on the distances between the metal and the Ca
carbons of all neighboring residues, no direct interaction was
identified between the metal and the protein. Therefore, no
further QM/MM refinements of the complexes were carried out
[33].
Results
Amino Acid Sequence of Fab 13G10 and Fab 14H7
13G10 and 14H7 are murine monoclonal antibodies that were
found to belong to the IgG1, l-class. The sequences of their
variable chains (Figure 2) differ by one residue in the light chain,
outside of the complementary determining regions (CDRs) [37],
and 17 residues in the heavy chain. In CDRH1, the sequences
differ at positions H23 (Lys/Thr), H28 (Thr/Ser), H30 (Thr/Ser)
and H34 (Met/Ile) for 13G10 and 14H7, respectively. CDRH2
has the same sequence in both antibodies. Their CDRH3, which is
a main determinant of the combining site, has the same length but
contains, in addition to Ser/Ala mutations at positions 93 and 97,
two different amino acids with the same hydrophobic nature at
position H100b (Ile/Leu) and H100c (Met/Leu).
Mature antibody genes are first formed by the assembly of the
variable (V) and junction (J) gene segments for the light chain
variable (VL) domain and by the assembly of the variable (V),
junction (J) and diversity (D) gene segments for the heavy chain
variable (VH) domain; affinity maturation then introduces into
antibodies somatic mutations that increase binding affinity to the
hapten or antigen [38]. For mice (Mus Musculus) antibodies, only
three germline Vlsegments (compared with 180 Vk segments),
and four Jl segments have been uncovered [39], which explains
the poor diversity of the l-light chain variable sequences
compared with the k-class. Compared with the germline Vl1/
Jl1 sequence [40], there is one difference in the variable light
chain of 13G10 and 14H7, Leu at position L96 (instead of Trp) in
CDRL3 that arises from diversity at the junction between the V
and J gene segments (Figure 2). In addition, 14H7 displays a Thr
instead of a Lys at position L39, which is located outside the
recombinant site. The nucleotide sequence of the 13G10 and
14H7 VH domains shows that they are derived from a gene in the
J558 family, the largest VH family. The 13G10 VH sequence has
highest homology to germline gene sequence J558.42 (98%
identity at the nucleotide level) [41]. This translates into 94 (resp.
87) identical amino acid residues out 98 in VH for 13G10 and
14H7, respectively (Figure 2). The nucleotide sequence indicates
that the VH region of antibodies 13G10 and 14H7 is encoded by
the combination of J558.42 with a D gene segment that could not
be identified because it is too short and JH4.
Comparison of the 13G10 and 14H7 VL and VH sequences to
that of the germline genes indicates that 13G10 and 14H7 did not
undergo much affinity maturation in the V segments. Among the
rare somatic mutations, the ones that belong to the combining sites
are LeuL96 (CDRL3), ValH50 (CDRH2) and SerH93 (CDRH3),
for 13G10 (Table 2, Figure 2). On the other hand, the exceedingly
hydrophobic nature of CDRH3 of 13G10 and 14H7 is due to
extensive affinity maturation in the D segment so that the germline
D segment could not be identified from the nucleotide sequence.
Alanine at position H101 comes from a somatic mutation.
Determination of the Structures of Fab 13G10 and Fab
14H7
The crystal structures of Fab 13G10 and Fab 14H7 were
determined at 2.05 A˚ and 2.55 A˚, respectively (Table 1). Fab
13G10 crystallized with one molecule in the asymmetric unit,
whereas the crystals of Fab 14H7 contained eight Fab molecules in
the asymmetric unit and were pseudomerohedrally twinned
[42,43,44]. Twinning was detected using the xtriage program
included in PHENIX [25]. The cumulative local intensity deviation
distribution statistics [45] did not indicate twinning:
,|L|.= 0.488 (untwinned: 0.500; perfect twin: 0.375);
,L2.= 0.319 (untwinned: 0.333; perfect twin: 0.200). However,
the results of the H-test [46] on acentric data gave a,|H|. value
of 0.046 (0.50: untwinned; 0.0:50% twinned) and a ,H2. value
of 0.005 (0.33: untwinned; 0.0:50% twinned). The estimation of
the twin fraction by the H-test was 0.454 compared with 0.425 by
Britton analysis [47] (Figure S1). The twinning law h, -k, -l and a
twinning fraction of 0.5 were used throughout the refinement
using PHENIX.
Overview of the Structures of Fab 13G10 and Fab 14H7
Fab 13G10 and Fab 14H7 display large elbow angles of 175.3u
and 170.1u, respectively, in agreement with their light chain
belonging to the l-class. The frameworks of the two Fabs
superimpose with an rmsd of 1.067 A˚2 over 174 Ca atoms.
However, the fit is better for the VL and VH domains taken
separately, with an rmsd of 0.54 A˚2 over 89 Ca atoms and 0.92 A˚2
over 85 Ca atoms, respectively. This reflects a difference in the
orientation of the VH and VL domains of the two antibodies with
respect to each other of 8.04u and 0.61 A˚. Together with the
different conformations of CDRH3 (see below), the combining site
of 14H7 is more open, with an accessible surface area of 19810 A˚2
compared with 18820 A˚2 for 13G10 (Figure 3A).
The hapten-binding pocket of 13G10 is a shallow cleft, roughly
12.7 A˚ by 7.2 A˚ wide and 8 A˚ deep, at the upper part of the VL/
VH interface (Figure 3B and 3C). Electron density could be
observed for a magnesium ion and two molecules of glycerol in the
combining site of Fab 13G10 (Figures 3B and 4A). The
magnesium ion likely indicates the position of the Fe(ToCPP)
iron in the hapten/antibody complex, thus confirming the location
of the catalytic pocket at the antibody combining site at the VL/
VH interface.
In 13G10, CDRH1 adopts the canonical structure H1-13-1
(Figure 4A) [37]. In 14H7, electron density is observed for
CDRH1 only for four molecules in the asymmetric unit out of
eight and it adopts a very different conformation from that in
13G10, which has not yet been listed (Figure 4B) [37]. This is a
consequence of the four differences in amino acids in this CDR
between the two antibodies. However, this difference in the Ca
backbone of CDRH1 does not contribute to create different
topologies in the combining sites because only AsnH33, whose side
Crystal Structures of 13G10 and 14H7
PLOS ONE | www.plosone.org 4 December 2012 | Volume 7 | Issue 12 | e51128
Figure 2. Amino acid sequences of the VL and VH domains of 13G10 and 14H7. Dots denote sequence identity to antibody 13G10. H
denotes the heavy chain and L the light chain. Numbering of the antibody residues follows the Kabat nomenclature [40] and the definition of the
hypervariable regions, indicated in bold, is from North et al. [37]. The sequence in italics has also been determined by Edman degradation of the
aminoterminal part of the protein. The nucleotide sequences of 13G10 and 14H7 have been deposited in the Genbank database, except for the
Crystal Structures of 13G10 and 14H7
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chain has two different conformations in the two antibodies,
together with HisH35, line the pocket (Figure 3C). CDRH2 adopts
the canonical structures H2-10-1 in both antibodies [37] but the
side chains of TyrH52 display very different conformations
(Figure 4C). CDRH3 in both antibodies does not share the same
conformation because of the flexibility of the main chain due to
the presence of three glycine residues (Figure 2). AsnH33, TyrH52
and the main chain of CDRH3 are in contact so that their
conformation depends on each other (Figure 4C). In both 13G10
and 14H7, CDRL1, CDRL2 and CDRL3 adopt the canonical
structures L1-14-1, L2-8-4 and L3-9-1, respectively [37]. The side
chain of TrpL91 in CDRL3 has different orientations in the two
antibodies (Figure 4C).
AsnH33, several residues of CDRH2 (TyrH52, AspH56,
SerH58 and the somatically mutated residue ValH50) and
CDRH3 form one face of the combining site (Figure 3B and
3C). The main residues lining the other face of the cavity are
TyrL32 and TrpL91. The bottom of the site is composed of
HisH35 and somatically mutated LeuL96. The identity of the
amino acids that define the combining site of 13G10 and 14H7 is
consistent with their belonging to the l-light chain class of
antibodies (Table 2). The very hydrophobic nature of the antigen-
binding site is not only due to the presence of Tyr, Trp and Leu
constant heavy chains whose sequences have not been determined: Genbank accession numbers 13G10H, AY178830; 13G10L, AY178831 for the
mRNA and AA020092, AA020093 for the corresponding protein sequence; 14H7H, AY178829; 14H7L, AY178828 for the mRNA and AA020092,
AA020093 for the corresponding protein sequence. The previously published amino acid sequences [14] were not those of antibodies 13G10 and
14H7. The germline sequences are indicated below the sequence of the antibodies.
doi:10.1371/journal.pone.0051128.g002
Table 2. Comparison of the aminoacids that contact small haptens in the structurally characterized l-light chain antibodies.
PDB code
13G10/
14H7*
Se155-4
1mfa [22]
CHA255
1ind [79]
NC10
1etz [83]
88C6/12
1yuh [80]
2D12.5
1nc2 [85]
RS2-G19
2ntf [82]
10G6
1jnh [84]
N1G9
1ngp [81]
L32 CDRL1 Tyr His Tyr Tyr Tyr Tyr Tyr Tyr Tyr
L34 – Asn Asn Asn Ile Asn Asn Asn Asn Asn
L91 CDRL3 Trp Trp Trp Trp Trp Trp Trp Trp Trp
L93 – Ser Asn Ser Ser Ser Ser Ser Ser Ser
L94 – Asn Asn Asn Asn Asn Asn Asn Asn Asn
L96 – Leu Trp Trp Trp Trp Trp Trp Phe Trp
H33 CDRH1 Asn Trp Thr Gly Leu Gly Trp Trp Trp
H35 – His His Ser Gly His His His Gln His
H47 FR2 Trp Trp Trp Leu Trp Trp Trp Trp Trp
H50 CDRH2 Val Ala Thr Asp Arg Val Thr Ala Arg
H52 – Tyr Tyr Leu Trp Asp Trp Tyr Tyr Asp
H52A – Pro Pro Ser Pro Pro Pro Pro
H53 – Gly Asn Gly Asn Asn Ser Gly Gly Asn
H56 – Asp Ala Phe Lys Val Gly Asn Asp Gly
H58 – Ser Phe Phe Tyr Lys Ala Tyr Arg Lys
H95 CDRH3 Gly Gly His Arg Tyr Arg Gly Gly Tyr
H96 – Gly Gly Arg Thr Ala Gly Ser Arg Asp
H97 – Ala/Ser His Phe Tyr Ser Leu Ser Tyr
H98 – Ser Cys Tyr Tyr Leu Tyr
H99 – Tyr Arg Pro Tyr Tyr Gly
H100 – Tyr Tyr Asn Ser
H100 – Tyr
H100 – Gly
H100 – Ser
H100 – Ser Asn
H100 – Gly Phe Tyr
H100 – Gly Tyr Tyr Asn Gly Tyr Ser
H100 – Ile Tyr Tyr Pro Tyr Trp Thr Tyr
H100 Met/Leu Gly Phe Met Phe Phe Met Phe
H101 Ala Asp Val Asp Asp Asp Gly Asp Asp
Underligned letters are residues that form direct or water-mediated hydrogen-bonds or salt-bridge to the hapten. A bold letter indicates that the residue is in van der
Waals contacts with the hapten.
*For 13G10 and 14H7, the hapten has been modeled by docking (see Table 3).
doi:10.1371/journal.pone.0051128.t002
Crystal Structures of 13G10 and 14H7
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residues at contact positions, as observed in other antibody
structures (Table 2). In addition, the CDRH3 loops of 13G10 and
14H7 are very peculiar in that they contain a high number of
glycine and alanine residues (H95-H100a) and only a few residues
with a long side-chain that could interact with the hapten
(Figure 2).
Figure 3. General view of the combining sites of Fab 13G10 and Fab 14H7. A Comparison of the binding site cavities of 13G10 and 14H7.
The VL frameworks of 13G10 (in blue) and 14H7 (in green) have been superimposed. The location of Mg2+ in 13G10 is indicated as a blue ball. B
General view of the active site of 13G10. CDRL1, CDRL2, CDRL3, CDRH1, CDRH2 and CDRH3 are shown as red, pink, orange, magenta, green and cyan
ribbons, respectively. Mg2+ and two glycerol molecules are indicated as blue ball and sticks, respectively. C Zoom of the combining site of 13G10.
doi:10.1371/journal.pone.0051128.g003
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Molecular Modeling of the a, a, a, b Hapten-antibody
Complexes
Because we did not succeed to grow crystals of Fab 13G10 and
Fab 14H7 in complex with the Fe(ToCPP) hapten, either by co-
crystallization or soaking, Fe(ToCPP) was modeled in the
recombinant site by molecular docking using the Gold 5.0 package
[34] and a previously reported protocol [33] (Figures 5A, 5E,
6A and 6E; Table 3). The docking solutions display the adjacent
a1 and a2 carboxyphenyl substituents deeply buried inside the
binding site, while those in a3 and b configuration are exposed
toward the solvent. The comparison of the accessible surface areas
of Fe(ToCPP) alone and in complex with 13G10 and 14H7
indicates that 53.7% and 44.9%, respectively, of the porphyrin is
buried in the antibody pocket.
In the most stable 13G10/Fe(ToCPP) predicted complex, the
hydrophobic CDRH3 loop stacks against the most buried
carboxyphenyl group of the porphyrin hapten (Figure 5A) and
must therefore have been specifically selected by the immune
system. Ligand recognition is achieved through H-bonds
(Figure 5A), van der Waals contacts and stacking interaction
(Table 3 and Figure 6A). In the calculated complex, the metal of
the porphyrin is located close to the magnesium atom that has
been characterized in the X-ray structure (Figure 3B and 4A,
Table 3). In the 20 first solutions with low energy for the 14H7/
Fe(ToCPP) complex, the porphyrin is always located in the
solvent-exposed region of the binding site (Figure 5E and 6E). This
leads to very variable orientations of the cofactor with weaker
complementarity to the antibody than in 13G10. The best solution
obtained for 14H7 is 10 kJ/mol less stable than that for 13G10
because of more extensive hydrophobic interactions in the case of
13G10 (Table 3). Indeed, while the hydrogen bonding energy is
the same for the two complexes, the lipophilic energy is about
Figure 4. Comparison of the CDRs of Fab 13G10 and Fab 14H7. A Peculiar conformation of CDRH1 in the combining site of Fab 13G10.
CDRH1 is shown as magenta sticks and a 2Fo-Fcalc map, contoured at 1 s and displayed around CDRH1, Mg2+ and the two glycerol molecules, as a
grey mesh. B Comparison of the conformations of CDRH1 in 13G10 and 14H7. CDRH1 in 14H7 and 13G10 are shown as magenta sticks and black
lines, respectively. The VH frameweworks of the two antibodies were superimposed. A 2Fo-Fcalc map contoured at 1 s is displayed around CDRH1 of
14H7 and shown as a grey mesh. C Comparison of the combining sites of Fab 13G10 (CDRs colored as in Fig. 4A) and Fab 14H7 (black).
doi:10.1371/journal.pone.0051128.g004
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100 kJ/mol lower in 13G10. Moreover, less clashes can be
observed in 14H7, compared with 13G10. These observations are
consistent with a lesser degree of complementarity between the
cofactor and the antibody in 14H7 than in 13G10. In the former,
the cofactor remains solvent exposed, with the most important
interactions taking place with TyrH32, TyrH52 and SerH97,
while in the latter, the cofactor binds more deeply inside the cavity
with the H-bonding interactions taking place with more buried
residues: AsnH33, HisH35 and the NH groups of GlyH96 and
GlyH100a.
Our models of the complexes of 13G10 and 14H7 with
Fe(ToCPP) indicate that no residue in the vicinity of the cofactor is
able to chelate the metal in either antibody. The nearest residue
(AsnH33 in 13G10 and TyrH32 in 14H7) has its Nd or OH atom
4 A˚ and 4.5 A˚ away, respectively, from the metal. Apparently, the
steric hindrance caused by the carboxyphenyl groups prevents the
iron from approaching any residue of the protein.
Rationalization of the Binding of Alternative Cofactors
To obtain better mimics of peroxidases, capable of binding one
imidazole ligand, complexes of 13G10 and 14H7 with less
hindered iron(III)-tetraarylporphyrins, bearing only one or two
carboxyphenyl substituents (monosubstituted Fe(MoCPP) and a,b
or a,a, di-substituted Fe(DoCPP)), were designed (Figure 1) [16].
Although all 13G10/porphyrin complexes were shown to bind
only one imidazole ligand, the affinity for imidazole of the a,a and
a,b-Fe(DoCPP) complexes was 2–3 fold lower than that of
13G10/Fe(ToCPP). Interestingly, the 13G10/dicarboxyphenyl
porphyrin complexes presented higher activity for ABTS oxidation
than the original Fe(ToCPP)/13G10 complex in the presence of
50 mM imidazole. The crystal structures provided in this work
combined with molecular modeling offer the opportunity to
rationalize such findings.
First, the mono and disubstituted porphyrins were docked into
the combining sites of the two antibodies (Figure 5B–D, 6B–D,
7A and B, Table 3). Overall, the four porphyrins have relatively
similar binding modes to 13G10, with a good complementarity of
a major part of the macrocycle with the binding site (Figure 6A–D
and 7A). A strong interaction between one of the porphyrin
carboxylates and both AsnH33 and HisH35 of CDRH1 is always
present and appears as the most important feature in the
recognition of the cofactors by 13G10. This is sustained by the
fact that the complexes with Fe(ToCPP) and Fe(MoCPP), despite
differing by three carboxylates and making five and three H-bonds
with 13G10, respectively, have similar binding energies (Table 3).
Thus, increasing the number of carboxylates in the cofactor does
not mean an overall better binding because it also increases steric
hindrance and results in more important bad contacts (Table 3).
Slight differences are still observed in the way the ligands penetrate
into the cavity, with aa-Fe(DoCPP) displaying the highest buried
surface, the lowest one being obtained for Fe(ToCPP).
Fe(MoCPP) binds to 14H7 in a very different way compared
with Fe(ToCPP) (Figure 7B). For ab-Fe(DoCPP), the binding
mode to 14H7 is very similar to that of Fe(ToCPP), while for aa-
Fe(DoCPP), the porphyrin is noticeably displaced. However,
overall, the binding modes of the three alternative cofactors are
similar in energy, including for its individual terms (Table 3).
Docking imidazole in the various porphyrin/13G10 complexes
indicates that two molecules of imidazole can bind the iron, one on
each side of the cofactor. However, imidazole binds preferentially
on opposite faces of the porphyrin, depending on the cofactor
(Figure 7C, D and E). For Fe(ToCPP), imidazole binds to the
solvent-exposed face, whereas in the case of the dicarboxylates-
containing porphyrins, it binds in the cavity formed between the
cofactor and the protein. The overall binding energies are very
similar and the main differences appear in the hydrogen bond and
lipophilic terms (Table 4).
Structural Basis of Catalysis: Comparison to the
Ferrochelatase and Porphyrin-dependent Peroxidase
Antibody 7G12
The structure of 13G10 can be compared with that of the k-
light chain metallochelatase and porphyrin-dependent peroxidase
antibody 7G12 (Fig. 8A and B). Antibody 7G12, induced against a
distorted N-methylmesoporphyrin IX, a transition state analogue
for porphyrin metalation [48], catalyzes the chelation of various
metals by mesoporphyrin IX. In addition, the complex of 7G12
with Fe(III)-mesoporphyrin IX was shown to catalyze the
oxidation of several chromogenic peroxidase substrates by
hydrogen peroxide with more than 200 turnovers with kcat of
6 s21 and kcat/Km of 300 M
21 s21 [49]. Thus, the peroxidase
activity of 7G12 is similar to that of 13G10. The crystal structure
of antibody 7G12 complexed with N-methylmesoporphyrin IX has
shown that the antibody induces geometric strain in the porphyrin
substrate to catalyze porphyrin metalation [50,51,52]. The
carboxylate side-chain of AspH96 of 7G12, which is positioned
1.9 A˚ from the center of the porphyrin ring (Fig. 8A), is thought to
act as a catalytic residue in the metal chelatase reaction by
Figure 5. Models of the complexes of 13G10 and 14H7 with the different porphyrins. The H-bonds between the antibodies and the
porphyrins are indicated. A 13G10/Fe(ToCPP). Molecular docking gives two most favorable orientations of Fe(ToCPP) bound to 13G10. In the most
stable 13G10/Fe(ToCPP) predicted complex, the carboxylate of the b substituent makes a H-bond with SerH58, while the a1 substituent is H-bonded
to AsnH33, HisH35, GlyH96 and GlyH100a. Only two bad contacts between the ligand and protein are observed in this orientation (Table 3). In the
second orientation (score 40.4 compared with 41.5, data not shown), this pair of interactions is inverted. B 13G10/Fe(MoCPP). The unique
carboxyphenyl substituent is plugged inside the binding site of 13G10, making hydrogen bonds with AsnH33, HisH35 and GlyH100a. One of the
phenyl substituents is also inserted into the cavity, while the two others remain solvent exposed. The predicted complex has a similar intermolecular
energy than the 13G10/Fe(ToCPP) complex, with no major bad contacts. C 13G10/aa-Fe(DoCPP). D 13G10/ab-Fe(DoCPP). For the two Fe(DoCPP)
derivatives, one of the carboxyphenyl substituents is anchored in the binding site of 13G10, while the other is exposed to the solvent. The buried
carboxylate makes hydrogen bonds with AsnH33, HisH35, GlyH100 and GlyH100a (Table 3). For aa-Fe(DoCPP), the second carboxylate is interacting
with AlaH97, while in its ab counterpart, it does not make any interaction. As a result, the calculated energy of the aa-Fe(DoCPP)/13G10 complex is
2 kJ/mol lower than that of the ab-Fe(DoCPP)/13G10 complex (Table 3). E 14H7/Fe(ToCPP). In the best 14H7/Fe(ToCPP) model, the main hydrogen
bonding interactions are formed between the a2 substituent and both SerH97 and TyrH32, and between the a1 substituent and TyrH52 (Table 3). A
weaker interaction occurs between the b substituent and AsnL94 and no major bad contacts are found between any residue and the porphyrin
cofactor. In other orientations with higher energies, the porphyrin iron is chelated by TyrL32, as observed with Fe(MoCPP). F 14H7/Fe(MoCPP). The
unique carboxylate substituent is interacting with TyrH52, whereas TyrL32 is chelating the metal atom. G 14H7/aa-Fe(DoCPP). H 14H7/ab-Fe(DoCPP).
For aa-Fe(DoCPP) and ab-Fe(DoCPP), the interactions of 14H7 with TyrH32 and SerH97, which were present in the 14H7/Fe(ToCPP) complex, are
maintained. Interestingly, in the ab-Fe(DoCPP)/13G10 complex, the interactions with SerH97 and TyrH32 are made with the same carboxylate group,
whereas, in aa-Fe(DoCPP)/13G10, one carboxylate substituent is interacting with TyrH32 and the other with SerH97. This leads to the reduction of
bad contacts in the latter case (Table 3).
doi:10.1371/journal.pone.0051128.g005
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deprotonating the substrate and chelating the metal [50]. For the
peroxidase reaction, AspH96 is too near to the center of the
porphyrin ring to act as a distal ligand but it is in an appropriate
position to act as a proximal ligand for the iron atom of Fe(III)-
mesoporphyrin IX. Hydrogen peroxide is expected to approach
the non-obstructed side of the porphyrin ring, opposite to AspH96,
which is surrounded only by hydrophobic residues such as TyrL49
and TyrL91. The active site of 7G12 does not reveal the presence
of distal ligands susceptible to enhance the peroxidase activity of
Fe(III)mesoporphyrin IX.
Directed and random mutagenesis were used to generate
libraries of 7G12, and antibodies with increased peroxidase
activity were selected by phage display using an activity-based
strategy [53]. A mutant, in which TyrL49 was replaced by Trp,
had a 10-fold increase in kcat/Km. In addition, two mutants bore
mutations thought to affect the packing between the porphyrin
ring and TyrL49 or TyrL91. Because TyrL49 and TrpL91 are
involved in p-stacking interactions with the porphyrin ring in the
7G12/N-methylmesoporphyrin IX complex (Fig. 8A), it was
proposed that the mutations could help to stabilize the radical
cation on the porphyrin ring and yield to higher peroxidase
activity [53].
In 13G10 and 7G12, a bulky residue preceding residue H101
(Met) is positioned at the bottom of the active site cavity, which
leads to shallow binding sites (Fig. 8). This positions the porphyrin
haptens at the surface of the combining site, contacting almost
exclusively residues of the CDRs. The larger elbow angle in l-light
chain antibody 13G10 coupled with a longer CDRH3 (H95–
H101) results in a shallower binding site in 13G10 compared with
7G12 (Fig. 8A and B). In contrast to 7G12, no residue is correctly
positioned to bind the iron in the 13G10-Fe(ToCPP) complex.
Discussion
Antibodies elicited against carefully designed transition state
analogues have been reported to catalyze a wide range of chemical
reactions [54,55,56,57,58,59]. However, the crystal structures of
these antibody catalysts have revealed that most antibodies
generally act by simple transition state stabilization [58,60,61]
and only a few utilize covalent chemistry [62,63,64,65]. The
incorporation of cofactors has been proposed as a possible strategy
to expand the catalytic scope of antibodies, in particular to lead to
redox catalysis [56]. Actually, the combination of the intrinsic
reactivity of a cofactor with the tailored binding specificity of an
antibody has been underutilized. However, cofactor and antibody
effectively complement each other: like in enzymatic catalysis, the
antibody enhances the catalytic efficiency of the cofactor and
ensures reaction specificity, stereospecificity and substrate speci-
ficity. Several antibodies raised against a porphyrin hapten and
possessing catalytic activity have been reported
[12,48,49,66,67,68,69,70,71,72]. Moreover, catalytic antibody-
cofactor complexes have been structurally characterized for a
periodate-dependent oxygenation catalyst [73,74], and a pyridox-
al-59-phosphate-dependent antibody that catalyzes the transami-
nation of D-amino acids [75].
Antibodies 13G10 and 14H7, induced against Fe(ToCPP), were
shown to display peroxidase activity in the presence of iron-
porphyrin cofactors. Biochemical studies had already given
insights into the interactions between the antibodies and the
cofactor. First, UV-visible studies have shown that the binding of
the porphyrin into the antibodies is not accompanied by a change
of the high spin state of the iron(III) and that the porphyrin binds
in a hydrophobic pocket [13]. Moreover, the antibodies possess
similar affinities for the metallated or non-metallated cofactor
(Kd = 3–5 nM) [14]. Altogether, these results indicated that no
amino acid binding the iron atom had been induced in the
antibody combining sites by the Fe(ToCPP) hapten. The
determination of the apparent dissociation constants for the
variously substituted porphyrins by competitive ELISA indicated
that the antibodies do not bind tetraphenylporphyrin and allowed
a model to be proposed, where two thirds of the porphyrin
macrocycle could be inserted in the binding pocket, with two
carboxylates in a,b positions being more specifically bound to the
protein [14]. Tetraaryl porphyrins bearing only one meso-ortho-
carboxyphenyl substituent could still bind 13G10 and 14H7,
although with a 50-fold reduction in affinity [14]. Finally,
absorption spectroscopy studies have shown that, whereas the
iron(III) of Fe(ToCPP) is able to bind two imidazole ligands, the
Fe(ToCPP)-13G10 complex can fix only one, which inhibits its
peroxidase activity [16].
All catalytic antibodies, whose crystal structure had been solved
until now, belonged to the 95% mouse antibodies that possess a k-
light chain [76], except one [77]. Many of these catalytic
antibodies share a deep combining site formed not only by
residues of the CDRs but also by residues of the framework
(Figure 8C) [58,61]. This observed structural convergence was due
in part to the use of similar hydrophobic haptens to induce the
antibodies. 13G10 and 14H7, elicited against a very different iron-
porphyrin hapten, belong to the IgG1, l class. As observed for
other catalytic antibodies [78], the mature genes of 13G10 and
14H7 display a high conservation degree with their germline
counterparts.
Among the few examples of crystal structures of murine Fabs
with l-type light-chain that have been solved, ten of them are
those of Fabs complexed with small haptens
[22,79,80,81,82,83,84,85] (Table 2) and several of them with a
peptide or protein antigen [86,87,88,89,90,91,92,93]. These
crystal structures have shown that the combining site of l-light
chain antibodies is formed by different amino acid residues than
that of k-light chain antibodies (Compare Table 2 with Table 2 of
reference [61]). In particular, the X-ray structures of antibodies of
different isotypes (l– and k– type) that bind to the same hapten
molecule have revealed drastically different binding modes of the
ligand [83,84,94]. It was therefore anticipated that catalytic
antibodies 13G10 and 14H7 will possess a combining site different
from that of previously crystallographically characterized k–light
chain catalytic antibodies and it was interesting to understand how
different they were.
The comparison of the cavity shapes of non hydrolytic catalytic
antibodies led to separate them into two categories, depending on
the nature of the residue preceding H101 [61]. Antibodies
possessing a small residue (ie. Gly, Ser) had a common deep
combining site, whereas those with a bulky residue (Phe, Met)
displayed shallow cavities with very different shapes. Antibodies
13G10 and 14H7 differ at this position, possessing Met and Leu,
respectively, and their structures reveal that their combining site
cavities is not very deep. In addition, their combining sites lie more
on the protein surface, compared with the other catalytic
antibodies possessing a bulky residue preceding H101
(Figure 8C). Because CDRH3 that is composed of several glycines
and residues with small side chains is predicted to be flexible, the
combining sites of the antibodies 13G10 and 14H7 do not share a
high similarity in shape although the two antibodies share a high
sequence similarity. Indeed, the deeper cavity observed in the
structure of 13G10 compared with 14H7 comes mainly from the
different conformations of CDRH3.
The structures of 13G10 and 14H7 indicate that the amino
acids prone to bind the ligand are the same as in the other l-light
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Figure 6. Molecular surfaces of the models of the complexes of 13G10 and 14H7 with the different porphyrins. Residues involved in
van der Waals and hydrophobic contacts are shown. A 13G10/Fe(ToCPP). B 13G10/Fe(MoCPP). C 13G10/aa-Fe(DoCPP). D 13G10/ab-Fe(DoCPP). E
14H7/Fe(ToCPP). F 14H7/Fe(MoCPP). G 14H7/aa-Fe(DoCPP). H 14H7/ab-Fe(DoCPP).
doi:10.1371/journal.pone.0051128.g006
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chain antibodies (Table 2), with only a few residues that belong to
the L chain taking part in the combining site, and CDRH2 making
an important contribution. About half of the hapten appears to be
buried in the combining sites of 13G10 and 14H7, with CDRH3
and residues TyrL32, TyrH52 and TrpL91 stacking against the
porphyrin ring (Figure 6). Although this accounts for the nM
affinity of the hapten for the antibodies, this is lower than the two
thirds predicted from the biochemical data [14], presumably
because induced fit is expected to occur in the complexes, which is
not taken into account in the calculated interactions. Molecular
docking predicts important differences for the recognition of
Fe(ToCPP) by the two antibodies. The shallower and wider
binding site of 14H7, as observed in the crystal structure, does not
allow the hapten to bind as deeply as it does in 13G10. Similar
results were obtained for the docking of the other cofactors
(Figure 7A and 7B).
Like in peroxidases, the heme environment of 13G10 and 14H7
consists of numerous hydrophobic residues. In heme peroxidases,
the iron atom is bound to the apoprotein by the proximal histidine.
This axial ligand was shown to be important for modulating the
redox potential of the iron and thus, the catalytic activity of the
enzyme [95]. However, our docking models indicate, in agreement
with the biochemical data, that no amino acid residue that binds
the iron has been induced in the combining sites of 13G10 and
14H7. The key step of the mechanism of peroxidases is usually the
cleavage of the O–O bond of H2O2 or ROOH, with the release of
a water molecule and formation of the highly reactive iron (V)-oxo
intermediate, assisted by the distal histidine and an arginine.
However, this function is fulfilled by a catalytic glutamate base
positioned 4.9 A˚ apart from the iron for a direct attack in
Caldariomyces fumago chloroperoxidase [96]. Neither induction by
the Fe(ToCPP) hapten itself, nor the use of differently substituted
porphyrin cofactors, led to the positioning of any histidine or
arginine residue in 13G10 or 14H7 that could participate in the
heterolytic cleavage of the O-O bond of peroxide, like in
peroxidases. However, previous biochemical results suggested that
a carboxylic acid side chain of antibody 13G10 could participate
in catalysis by protonating one of the oxygen atom of H2O because
it was shown that kcat increases sharply below pH 5 for the 13G10-
Fe(ToCCP) complex [15]. However, no COOH side-chain of the
13G10 antibody is correctly localized to act as a general acid-base
catalyst. Indeed, the only carboxylic acid side-chain in the
combining site of 13G10 that could play a role in catalysis
belongs to AspH56 (Table 3, Fig. 3C, 4C, 5, 6 and 8A). However,
its nearest oxygen atom is positioned 10.6 A˚ away from the iron, a
distance that necessitates a mediating water molecule for AspH56
to act as a general acid catalyst in the peroxidase reaction. Acid
catalysis by the ortho carboxylate group of iron (II) [meso-(ortho-
carboxyphenyltriphenyl-porphyrin has previously been proposed
in aldoxime dehydration via the protonation of the substrate
hydroxy group [97]. Thus, one of the two buried carboxylate
groups of the hapten could fulfill the same function in the 13G10-
Fe(ToCCP) complex. Our models of the porphyrin-13G10
complexes reveal that, in addition to them, the polar residues
best positioned to play a role in catalysis are AsnH33 and TyrH52,
also located on the buried side of the porphyrin (Figure 5 A–D).
H2O2 could bind on the same sheltered face of the porphyrin ring,
Figure 7. Comparison of the binding of the different porphy-
rins to 13G10 and 14H7 and models of imidazole binding to
the 13G10/porphyrin complexes. Stereoviews of the superposition
of the different porphyrins in the combining sites of 13G10 (A) and
14H7 (B). Fe(ToCPP), aa-Fe(DoCPP), ab-Fe(DoCPP) and Fe(MoCPP) are
colored green, blue, yellow and red, respectively. For 13G10, the
porphyrins of Fe(MoCPP), aa-Fe(DoCPP) and ab-Fe(DoCPP) superim-
pose onto that of Fe(ToCPP)(without taking into account the
carboxylate substituents) with rmsds of 0.5, 3.0 and 1.7 A˚2, respectively.
For 14H7, the porphyrins of Fe(MoCPP), aa-Fe(DoCPP) and ab-
Fe(DoCPP) superimpose onto that of Fe(ToCPP) with rmsds of 9.1, 3.1
and 0.9 A˚2, respectively. C Model of imidazole bound to 13G10/
Fe(ToCPP). The binding of the imidazole molecule is favored by an H-
bonding interaction with the main chain of AlaL93. D Model of
imidazole bound to 13G10/aa-Fe(DoCPP). Despite some clashes,
imidazole binding is stabilized by H-bonds with AsnH33 and one of
the buried carboxylates. Stabilization is also achieved by hydrophobic
contacts as imidazole binds in the cavity left between the cofactor and
the protein. E Model of imidazole bound to 13G10/ab-Fe(DoCPP).
Imidazole is located on the buried side of the porphyrin but does not
make any interaction with the protein, the b-carboxylate being oriented
toward the solvent.
doi:10.1371/journal.pone.0051128.g007
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in a hydrophobic pocket similar to that present in horseradish
peroxidase [98]. This location of the binding site of hydroperoxide
would explain the remarkable thermostability of the cofactor-
antibody complex and the multiple turnovers of the reaction. In
cytochrome c oxidase, the radical cation in the iron(IV)oxopor-
phyrin intermediate was delocalized onto the indole ring of
TrpL91 [8]. Similarly, it was proposed that TyrL49 and TyrL91
that stack against the porphyrin ring of the hapten could fulfill a
similar function in catalytic antibody 7G12 and enhance the
peroxidase activity of the 7G12/Fe(III)mesoporphyrin complex
[53]. In the models of 13G10 and 14H7 with the different
porphyrins, TrpL91, TyrL32 and TyrH52, which are predicted to
stack against the porphyrin ring (Fig. 6), could act in the same way.
Imidazole was used as an iron ligand that might mimic the
proximal histidine in the 13G10/porphyrin complexes. Molecular
docking indicates that imidazole preferentially binds on opposite
faces of the porphyrin ring in the 13G10/Fe(ToCPP) and 13G10/
Fe(DoCPP) complexes (Figure 7C to E). Imidazole is predicted to
bind to the solvent-exposed face of Fe(ToCPP), which might
hinder binding of the hydroperoxide substrate to the sheltered face
of the cofactor and lead to the inhibition of the peroxidase activity.
In contrast, imidazole is predicted to bind in the cavity formed
between 13G10 and aa- or ab-Fe(DoCPP) (Figure 7D and E),
which likely represents a higher affinity site and would explain that
the affinity for imidazole of the a,a- and a,b-1,2-Fe(DoCPP)
complexes was 2–3 fold lower than that of 13G10/Fe(ToCPP). In
this manner, imidazole would be located appropriately to act as
the proximal histidine. In this case, hydroperoxide would bind on
the solvent-exposed face of the porphyrin and TyrL32 could assist
in the cleavage of the O-O bond of hydroperoxide by functioning
as an acid catalyst. In the case of ab-Fe(DoCPP), the b carboxylate
of could also play this role. This would account for the 8–9–fold
enhancement of the catalytic efficiency of the peroxidase reaction
in the presence of 50 mM imidazole, when 13G10 is complexed
with the di-substituted cofactors compared with Fe(ToCPP).
In the future, better catalysts could be obtained by directed
mutagenesis of 13G10 and 14H7. Replacing AsnH33 by a
histidine in 13G10 could lead to the binding of its imidazole group
to the iron atom of Fe(ToCPP), which could enhance the
peroxidase activity of the 13G10/porphyrin complex. Indeed,
antibodies induced against microperoxidase 8 that were shown to
possess an axial histidine coordinating the iron atom had a better
peroxidase activity than 13G10 and 14H7 [99,100]. Mutating
TyrL32 to histidine or arginine to generate a better acid catalyst or
an amino acid that enhances the polarization of the O-O bond
could also increase the catalytic activity of the 13G10/
Fe(DoCPP)/imidazole complexes. Alternatively, antibodies with
enhanced peroxidase activity could be obtained by phage display
using an activity-based strategy for selecting oxidative catalysts, as
described previously [53].
Conclusion
Understanding the structure-function relationship of catalytic
antibodies with a l-light chain is important to shed light on the
diversity of catalytic antibodies, which may help to broaden the
scope of these catalysts. The anti-porphyrin antibodies 13G10 and
14H7, with a l-light chain, were shown to possess shallow hapten
binding pockets compared with the other structurally character-
ized catalytic antibodies. The structural complementarity of the
Fe(ToCPP) cofactor to the hydrophobic binding pocket of
antibodies 13G10 and 14H7 leads to a remarkable thermostability
of the cofactor-antibody complexes and allows multiple turnovers
of the peroxidase reaction. Molecular modeling indicates that the
recognition of various porphyrins with different carboxyphenyl
substituents is achieved mainly by stacking interactions but also by
crucial hydrogen bonds with two or three carboxylate groups. Our
models explain why one carboxyphenyl substituent is sufficient for
a good affinity of the porphyrin cofactor for 13G10 and 14H7.
CDRH1 and CDRH3 appear to play key roles for binding
Fe(ToCPP) and no proximal ligand of the iron was induced in
13G10 and 14H7. The increase of the peroxidase activity of the
cofactor, when bound to the antibodies, could be explained by a
loss of entropy due to accessibility of H2O2 to only one of the two
faces of the porphyrin ring, and possibly by the stacking of several
aromatic groups onto the porphyrin ring that would stabilize the
radical cation in the iron(IV)oxoporphyrin intermediate in the
peroxidase reaction. Moreover, one of the buried carboxylic group
of the porphyrin substituents may also participate as a general acid
catalyst, with the implication that H2O2 would bind on the
sheltered face of the porphyrin ring. The carboxylic group would
facilitate the heterolytic cleavage of the O-O bond, with the release
of a water molecule and formation of the highly reactive iron (V)-
oxo intermediate. Interestingly, an imidazole ligand that mimics
the proximal histidine in peroxidases can be modeled in the
complexes of 13G10 with aa-Fe(DoCPP) and ab-Fe(DoCPP) on
the sheltered face of the porphyrin ring, with TyrL32 correctly
positioned to act as an acid catalyst, in agreement with these
complexes showing higher catalytic efficiency compared with
Fe(ToCPP), in the presence of imidazole. The similar binding
energies of 13G10 and 14H7 for the alternative cofactors and the
original hapten open novel possibilities for developing other
porphyrinic-based cofactors for these antibodies. In future work, in
order to obtain catalytic antibodies that mimic cytochromes P450,
one should design a substituted porphyrin hapten that generates
binding sites for the substrate in addition to that of the
metalloporphyrin in the antibodies.
Table 4. Statistical analysis of the lowest energy structures for the docking of imidazole in the 13G10/Fe(ToCPP) and 13G10/
Fe(DoCPP) models.
Antibody Ligand Score
DGbinding
(kJ/mol) Shbond
Hydrogen bonding
Interactions
(distances in A˚) Smetal Slipo Sclash
Clashes
(distances
in A˚)
13G10 Fe(ToCPP) 22.61 223.08 0.98 AlaL93-O (2.64) 0.9 76.42 0.47 –
aa–Fe(DoCPP) 21.54 222.87 0.63 COO2 (2.65) 0.81 88.96 1.33 AsnH33 (2.45)
AsnH33 ND (2.96) Fe (2.62)
ab–Fe(DoCPP) 19.88 219.93 0.0 – 0.9 77.21 0.05 –
doi:10.1371/journal.pone.0051128.t004
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Figure 8. Comparison of Fab 13G10 with other catalytic antibodies. A Comparison of the combining sites of the two porphyrin-dependent
peroxidase antibodies 13G10 and 7G12. The a-carbons of the framework of the heavy chain variable domain of 7G12 (in orange) have been
superimposed on those of 13G10 (in yellow), which results in a large variation in the positions of the light chain variable domains (VL 7G12 in
magenta and VL 13G10 in pink). The rms deviation of 0.964 A˚ reflects the different packing of the VH and VL domains in l-light chain antibodies
(13G10) and k-light chain antibodies (7G12). The hapten of 13G10 is represented in blue and that of 7G12 in red. B Comparison of the cavity
deepness of antibodies 13G10 (in blue) and 7G12 (in orange). A section of the molecular surface of the combining site of antibody 13G10 is colored in
yellow for the heavy chain and pink for the light chain. C Comparison of the cavity shapes of the nonhydrolytic catalytic antibodies with a bulky
residue at position preceding H101. 15A9 (yellow), PDB code 2BMK; 28B4 (red), PDB code 1KEL; 1E9 (green), PDB code 1C1E; 34D4 (cyan), PDB code
1Y18; 1D4 (magenta), PDB code 1JGU.
doi:10.1371/journal.pone.0051128.g008
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Data deposition. The atomic coordinates and structure
factors of Fab13G10 and Fab14H7 have been deposited at the
Protein Data Bank (PDB codes 4amk and r4amksf, and 4at6 and
r4at6sf, respectively).
Supporting Information
Figure S1 Detection of twinning and determination of
the twin fraction in the 14H7 crystals. A Estimation of the
twin fraction a by Britton plot analysis. The percentage of negative
intensities after detwinning is plotted as a function of the assumed
value of a. The estimated value of a is extrapolated from the linear fit
(green line). B Estimation of the twin fraction a using the H-plot. The
cumulative fractional intensity difference of acentric twin-related
intensities H {H = |I(h 1) 2 I(h 2)|/[I(h 1) + I(h 2)]} is plotted against
H. The initial slope (green line) of the distribution is a measure of a.
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